Eli Lilly and Company (NYSE:LLY) Stock Position Raised by Visionary Wealth Advisors

Visionary Wealth Advisors increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,153 shares of the company's stock after purchasing an additional 471 shares during the period. Visionary Wealth Advisors' holdings in Eli Lilly and Company were worth $1,662,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FPC Investment Advisory Inc. boosted its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $50,000. Fiduciary Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $58,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY traded down $1.21 during midday trading on Friday, hitting $713.99. The company had a trading volume of 2,631,160 shares, compared to its average volume of 3,622,393. The company's 50 day moving average price is $789.29 and its 200 day moving average price is $803.19. The stock has a market cap of $676.67 billion, a price-to-earnings ratio of 60.97, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.